ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1613843
This article is part of the Research TopicAdvances in Diagnosis and Treatment of Endometrial CancerView all 8 articles
Establishment and validation of a nomogram model for predicting early death in patients with endometrial cancer bone metastases
Provisionally accepted- 1Nanjing Medical University, Nanjing, China
- 2Department of gynecology, The Affiliated Huai’an NO.1 People's Hospital of Nanjing Medical University, Huai'an, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Patients with endometrial cancer bone metastases (ECBM) are clinically rare and have a poor prognosis, including a higher incidence of early death (survival ≤ 3 months). Currently, no practical tools exist to predict early mortality in these patients. Thus, there is an urgent need to develop clinically applicable predictive models, such as nomograms, for individualized assessment of early death risk in ECBM. Methods: Relevant clinical and pathological data for ECBM patients from the SEER database (2010-2021). Univariate and multivariate logistic regression analyses were performed to identify risk factors associated with early death in ECBM patients and to construct prognostic nomograms. ROC analysis, calibration curves, and decision curve analysis (DCA) were used to assess the predictive accuracy and clinical utility of the nomogram model. Results: A total of 1,201 ECBM patients were found in the SEER database. After applying strict exclusion criteria, 769 patients were finally included in this study. Patients were randomly divided into training and validation cohorts in a 7:3 ratio. The results of univariate and multivariate logistic regression analyses revealed several independent predictive factors for early death. For both overall early death (OED) and cancer-specific early death (CSED), protective factors included surgery (OED: OR=0.22, 95%CI: 0.12-0.41, p<0.001; CSED: OR=0.33, 95%CI: 0.18-0.61, p<0.001) and chemotherapy (OED: OR=0.11, 95%CI: 0.06-0.18, p<0.001; CSED: OR=0.14, 95%CI: 0.09-0.24, p<0.001). Brain metastases increased risk (OED: OR=2.98, 95%CI: 1.29-6.87, p=0.01; CSED: OR=2.20, 95%CI: 1.04-4.79, p=0.047). Compared to 0-9 days, longer time from diagnosis to treatment showed protective associations: 10-27 days (OED: OR=0.51, 95%CI: 0.27-0.98, p=0.042) and ≥28 days (OED: OR=0.23, 95%CI: 0.12-0.44, p<0.001; CSED: OR=0.30, 95%CI: 0.16-0.56, p<0.001). Regarding histological type, compared to endometrioid subtype, sarcomatous subtype significantly increased OED risk (OR=3.04, 95%CI: 1.40-6.57, p=0.005), while radiotherapy reduced CSED risk (OR=0.55, 95%CI: 0.33-0.92, p=0.022). Based on these variables, nomograms were developed to predict the risk of early death. The ROC curve confirmed the model’s high predictive accuracy, while the calibration curve showed strong alignment between predicted and actual survival. DCA further demonstrated its clinical utility. Conclusion: In this study, we developed robust nomogram models to predict the probability of early death in ECBM patients.
Keywords: endometrial carcinoma, Bone Metastases, early death, SEER database, nomogram
Received: 17 Apr 2025; Accepted: 17 Sep 2025.
Copyright: © 2025 Tang, Sun and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yingchun Gao, gych691222@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.